These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28469732)

  • 1. The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.
    Cohen SA; Yu M; Baker K; Redman M; Wu C; Heinzerling TJ; Wirtz RM; Charalambous E; Pentheroudakis G; Kotoula V; Kalogeras KT; Fountzilas G; Grady WM
    Clin Epigenetics; 2017; 9():46. PubMed ID: 28469732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability.
    Flatin BTB; Vedeld HM; Pinto R; Langerud J; Lind GE; Lothe RA; Sveen A; Jeanmougin M
    Int J Cancer; 2021 Apr; 148(7):1652-1657. PubMed ID: 33284993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci.
    Kawasaki T; Ohnishi M; Nosho K; Suemoto Y; Kirkner GJ; Meyerhardt JA; Fuchs CS; Ogino S
    Mod Pathol; 2008 Mar; 21(3):245-55. PubMed ID: 18204436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.
    Ogino S; Kawasaki T; Kirkner GJ; Kraft P; Loda M; Fuchs CS
    J Mol Diagn; 2007 Jul; 9(3):305-14. PubMed ID: 17591929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
    Kim JH; Bae JM; Cho NY; Kang GH
    Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP).
    Schernhammer ES; Giovannucci E; Baba Y; Fuchs CS; Ogino S
    PLoS One; 2011; 6(6):e21102. PubMed ID: 21738611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
    Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
    Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.
    Kim JH; Cho NY; Bae JM; Kim KJ; Rhee YY; Lee HS; Kang GH
    Int J Clin Exp Pathol; 2015; 8(2):1920-8. PubMed ID: 25973084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer.
    Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS
    Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
    Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM
    Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cimp-Positive Status is More Representative in Multiple Colorectal Cancers than in Unique Primary Colorectal Cancers.
    Tapial S; Olmedillas-López S; Rueda D; Arriba M; García JL; Vivas A; Pérez J; Pena-Couso L; Olivera R; Rodríguez Y; García-Arranz M; García-Olmo D; González-Sarmiento R; Urioste M; Goel A; Perea J
    Sci Rep; 2019 Jul; 9(1):10516. PubMed ID: 31324877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unmasking early colorectal cancer clues: in silico and in vitro investigation of downregulated IGF2, SOCS1, MLH1, and CACNA1G in SSA polyps.
    Mirbahari SN; Fatemi N; Savabkar S; Chaleshi V; Zali N; Taleghani MY; Mirzaei E; Rejali L; Moghadam PK; Mojarad EN
    Mol Biol Rep; 2024 Jun; 51(1):764. PubMed ID: 38874740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
    Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
    Zhang X; Shimodaira H; Soeda H; Komine K; Takahashi H; Ouchi K; Inoue M; Takahashi M; Takahashi S; Ishioka C
    Int J Clin Oncol; 2016 Dec; 21(6):1091-1101. PubMed ID: 27435270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
    Shiovitz S; Bertagnolli MM; Renfro LA; Nam E; Foster NR; Dzieciatkowski S; Luo Y; Lao VV; Monnat RJ; Emond MJ; Maizels N; Niedzwiecki D; Goldberg RM; Saltz LB; Venook A; Warren RS; Grady WM;
    Gastroenterology; 2014 Sep; 147(3):637-45. PubMed ID: 24859205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.
    Cha Y; Kim KJ; Han SW; Rhee YY; Bae JM; Wen X; Cho NY; Lee DW; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Kang GH; Kim TY
    Br J Cancer; 2016 Jul; 115(2):164-71. PubMed ID: 27310704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the CpG island methylator phenotype on survival outcome in colon cancer.
    Kang KJ; Min BH; Ryu KJ; Kim KM; Chang DK; Kim JJ; Rhee JC; Kim YH
    Gut Liver; 2015 Mar; 9(2):202-7. PubMed ID: 25167802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.
    Ogino S; Kawasaki T; Kirkner GJ; Ohnishi M; Fuchs CS
    BMC Cancer; 2007 May; 7():72. PubMed ID: 17474983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage III colorectal cancer: molecular disparity between primary cancers and lymph node metastases.
    Messick CA; Church JM; Liu X; Ting AH; Kalady MF
    Ann Surg Oncol; 2010 Feb; 17(2):425-31. PubMed ID: 19885699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
    Min BH; Bae JM; Lee EJ; Yu HS; Kim YH; Chang DK; Kim HC; Park CK; Lee SH; Kim KM; Kang GH
    BMC Cancer; 2011 Aug; 11():344. PubMed ID: 21827707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.